Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001527166 XXXXXXXX LIVE 4 Voting Common Stock, par value $0.0001 per share 02/18/2026 false 0001788028 471871202 Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City CA 94065 Jeffrey Ferguson (202) 729-5626 The Carlyle Group 1001 Pennsylvania Avenue, NW, Suite 220S Washington DC 20004 0001527166 N The Carlyle Group Inc. OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 CO 0001548626 N Carlyle Holdings I GP Inc. OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 CO 0001548627 N Carlyle Holdings I GP Sub L.L.C. OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 OO Limited Liability Company 0001548628 N Carlyle Holdings I L.P. OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 PN 0001790577 N CG Subsidiary Holdings L.L.C. OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 OO Limited Liability Company 0000933790 N TC Group, L.L.C. OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 OO Limited Liability Company 0001354120 N Carlyle Investment Management L.L.C. OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 OO Limited Liability Company 0001941860 N Carlyle Genesis UK LLC OO N DE 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 OO Limited Liability Company 0001397144 N Abingworth LLP OO N X0 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 PN 0001688313 N Abingworth Bioventures VII LP OO N X0 0.00 1088310.00 0.00 1088310.00 1088310.00 N 3.8 PN Voting Common Stock, par value $0.0001 per share Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City CA 94065 Explanatory Note This Amendment No. 4 to Schedule 13D ("Amendment No. 4") amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the "SEC") on October 4, 2021 (as amended to date, the "Schedule 13D"), relating to the shares of voting common stock, par value $0.0001 per share (the "Common Stock"), of Jasper Therapeutics, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D. Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, based on 27,984,039 shares of Common Stock outstanding as of November 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 10, 2025. Abingworth Bioventures VII LP is the beneficial owner of 1,088,310 shares of Common Stock, or approximately 3.8% of the shares of Common Stock outstanding, which include (i) 1,066,189 shares of Common Stock held of record by Abingworth Bioventures VII LP, (ii) 2,117 shares of Common Stock held for the benefit of Abingworth Bioventures VII LP and (iii) 20,004 shares of Common Stock underlying stock options held for the benefit of Abingworth Bioventures VII LP. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VII LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities. Sole power to vote or to direct the vote: 0 Shared power to vote or to direct the vote: 1,088,310 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or to direct the disposition: 1,088,310 During the past 60 days, the Reporting Persons have not effected any transactions with respect to the Common Stock. None. As of the date hereof, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding shares of Common Stock. The Carlyle Group Inc. /s/ Anne K. Frederick Anne K. Frederick, Corporate Secretary 02/18/2026 Carlyle Holdings I GP Inc. /s/ Anne K. Frederick Anne K. Frederick, Managing Director 02/18/2026 Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member, /s/ Anne K. Frederick Anne K. Frederick, Managing Director 02/18/2026 Carlyle Holdings I L.P. /s/ Anne K. Frederick Anne K. Frederick, Managing Director 02/18/2026 CG Subsidiary Holdings L.L.C. /s/ Anne K. Frederick Anne K. Frederick, Managing Director 02/18/2026 TC Group, L.L.C. /s/ Anne K. Frederick Anne K. Frederick, Managing Director 02/18/2026 Carlyle Investment Management L.L.C. /s/ Anne K. Frederick Anne K. Frederick, Managing Director 02/18/2026 Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member, /s/ Anne K. Frederick Anne K. Frederick, Managing Director 02/18/2026 Abingworth LLP /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory 02/18/2026 Abingworth Bioventures VII LP /s/ Emma O'Reilly Emma O'Reilly, Authorized Signatory 02/18/2026